Go Pro
→ The next convergence is here (From Digest Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aditxt, Inc. stock logo
ADTX
Aditxt
$0.00
-6.5%		$0.00
$0.00
▼
$26,604.72
$4K1.2197.25 million shs21.88 million shs
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
$0.00
$0.00
▼
$0.00
$6K1.6183,499 shsN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$0.00
$0.00
▼
$0.05
$10K1.767,146 shsN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$0.00
$0.00
$0.00
▼
$0.02
$11K1.3115,605 shs1,300 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aditxt, Inc. stock logo
ADTX
Aditxt
-4.44%-31.75%-14.00%-89.69%-100.00%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.00%0.00%0.00%0.00%0.00%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.00%0.00%0.00%0.00%+100.00%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00%0.00%+300.00%+300.00%-33.33%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aditxt, Inc. stock logo
ADTX
Aditxt
$0.00
-6.5%		$0.00
$0.00
▼
$26,604.72
$4K1.2197.25 million shs21.88 million shs
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
$0.00
$0.00
▼
$0.00
$6K1.6183,499 shsN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$0.00
$0.00
▼
$0.05
$10K1.767,146 shsN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$0.00
$0.00
$0.00
▼
$0.02
$11K1.3115,605 shs1,300 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aditxt, Inc. stock logo
ADTX
Aditxt
-4.44%-31.75%-14.00%-89.69%-100.00%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.00%0.00%0.00%0.00%0.00%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.00%0.00%0.00%0.00%+100.00%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00%0.00%+300.00%+300.00%-33.33%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aditxt, Inc. stock logo
ADTX
Aditxt
1.00
SellN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.00
N/AN/AN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.00
N/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ADTX, SYRS, NAVB, and GNCA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2026
Aditxt, Inc. stock logo
ADTX
Aditxt
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (E+) ➝ Sell (E)
(Data available from 9/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aditxt, Inc. stock logo
ADTX
Aditxt
$14.34K0.24N/AN/A$259.70 per share0.00
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
$1.91M0.00N/AN/A$0.47 per share0.00
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$8.13K0.00N/AN/AN/ANaN
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$386K0.03N/AN/A$0.79 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aditxt, Inc. stock logo
ADTX
Aditxt
-$41.71M-$100,788.35N/AN/AN/A-360,152.50%-374.60%-105.93%12/2/2026 (Estimated)
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
-$33.20M-$0.61N/AN/AN/AN/A-182.88%-62.76%N/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
-$15.18M-$0.21N/AN/AN/AN/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
-$164.57M-$3.03N/AN/AN/AN/A-3,369.56%-97.04%10/29/2026 (Estimated)
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aditxt, Inc. stock logo
ADTX
Aditxt
N/AN/AN/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
N/AN/AN/AN/AN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aditxt, Inc. stock logo
ADTX
Aditxt
N/A
0.06
0.05
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.24
1.35
1.35
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
N/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/A
2.25
2.25

Institutional Ownership

CompanyInstitutional Ownership
Aditxt, Inc. stock logo
ADTX
Aditxt
15.54%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.64%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.01%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
91.47%

Insider Ownership

CompanyInsider Ownership
Aditxt, Inc. stock logo
ADTX
Aditxt
0.01%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
1.61%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
43.68%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
12.26%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aditxt, Inc. stock logo
ADTX
Aditxt
60816,000816,000No Data
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
7058.73 million57.79 millionNot Optionable
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
10100.08 million56.37 millionNo Data
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
6826.83 million23.54 millionNo Data

Recent News About These Companies

Syros Announces Pricing of $75.6 Million Public Offering of Common Stock
July 14, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20210119006194/en/Syros-Announces-Pricing-of-%2475.6-Million-Public-Offering-of-Common-Stock
Rege Nephro buys Tamibarotene-related assets from Syros Pharmaceuticals
April 15, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/rege-nephro-buys-tamibarotene-related-assets-from-syros-pharmaceuticals/ar-AA1CX7u7
Syros Pharmaceuticals trading resumes
March 1, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/syros-pharmaceuticals-trading-resumes-1034427505
Syros Pharmaceuticals Plans to Wind Down Operations
March 1, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/syros-pharmaceuticals-plans-to-wind-down-operations-948b139e
Syros Pharmaceuticals voluntarily delists from Nasdaq, deregisters common stock
March 1, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/syros-pharmaceuticals-voluntarily-delists-from-nasdaq-deregisters-common-stock-1034427422
Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration
February 28, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250228459350/en/syros-announces-voluntary-delisting-from-nasdaq-and-sec-deregistration/
Syros Pharmaceuticals stock hits 52-week low at $0.18 amid steep decline
January 29, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/syros-pharmaceuticals-stock-hits-52-week-low-at-0-18-amid-steep-decline/ar-AA1y4cfB
Syros Pharmaceuticals Inc (SYRS) Stock Price Reaches $0.22: What Factors Are Influencing This Level?
January 18, 2025  |  bovnews.comB
What’s Causing Syros Pharmaceuticals Inc (SYRS) Stock’s -96.35% Drop Over the Last Six Months?
January 16, 2025  |  bovnews.comB
SYRS’s Latest Surge: What’s Behind the Spike?
January 6, 2025  |  bovnews.comB
The SYRS Conundrum: Why Syros Pharmaceuticals Inc’s Stock Is Making Headlines Again
January 2, 2025  |  bovnews.comB
Analysts Predict a $15 Target for Syros Pharmaceuticals Inc (SYRS) Stock—What Could Drive It There?
December 31, 2024  |  bovnews.comB
Syros Pharmaceuticals Inc (SYRS) Stock: More Resilient Than It Appears
December 27, 2024  |  bovnews.comB
Syros Pharmaceuticals Inc (SYRS) Stock Dive: The Hidden Causes Revealed
December 26, 2024  |  bovnews.comB
What’s Fueling Syros Pharmaceuticals Inc (SYRS) Stock’s -94.59% Loss Below Its 200-Day SMA?
December 14, 2024  |  bovnews.comB
Syros Pharmaceuticals Inc (SYRS) Stock Settles at $0.24: What’s Contributing to This Price Point?
December 7, 2024  |  bovnews.comB
Why Did Syros Pharmaceuticals Inc (SYRS) Stock Plunge -1.67% Last Week?
December 5, 2024  |  bovnews.comB
Nancy A. Simonian Sells 37,070 Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Stock
December 5, 2024  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-syrs-insider-buying-and-selling-2024-12-05/
Syros Pharmaceuticals Inc (SYRS) Stock Rated Buy by H.C. Wainwright
December 2, 2024  |  bovnews.comB
Why Is Syros Pharmaceuticals Inc (SYRS) Stock Lagging Behind -84.72% from Its 50-Day SMA?
November 29, 2024  |  bovnews.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aditxt stock logo

Aditxt NASDAQ:ADTX

$0.0043 0.00 (-6.52%)
As of 09/21/2026 03:59 PM Eastern

Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

Genocea Biosciences stock logo

Genocea Biosciences NASDAQ:GNCA

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

Navidea Biopharmaceuticals stock logo

Navidea Biopharmaceuticals NYSE:NAVB

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

Syros Pharmaceuticals stock logo

Syros Pharmaceuticals NASDAQ:SYRS

$0.0004 0.00 (0.00%)
As of 09/21/2026 12:11 PM Eastern

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas